CER Daily Newsfeed

Once-Weekly Insulin Efsitora Demonstrates Comparable Efficacy to Daily Basal Insulin in Type 2 Diabetes

(3/5, Luke Halpern, Pharmacy Times) reports “A systematic review and meta-analysis published in Diabetes, Obesity and Metabolism found that once-weekly insulin efsitora alfa (efsitora; Eli Lilly and Company) demonstrated comparable glycemic efficacy and superiority in reduction of hemoglobin A1C (HbA1C) at 52 weeks compared with once-daily basal insulin in adults with type 2 diabetes (T2D). The analysis provides pooled evidence supporting the clinical utility of this novel weekly basal insulin as an alternative to daily injection regimens.” Full

Prasad Out At FDA, Turning Critics' Focus Back To Makary

(3/6, Jessica Karins, Maaisha Osman, Inside Health Policy) reports “...Diana Zuckerman, president of the National Center for Health Research, told IHP Prasad's departure from CBER represents a setback for efforts to strengthen scientific rigor in the agency's regulatory decisions. She said Prasad brought a focus on scientific evidence that many researchers and policy experts have long argued has been missing at senior levels of FDA...In her view, the agency's reliance on more ‘flexible’ approval standards for products that lack clear evidence of benefit is contributing to rising health care costs and straining federal programs such as Medicare and Medicaid. ‘I think Dr. Prasad leaving is a loss for the FDA, for patients, and for Medicare and Medicaid,’ Zuckerman said.” Subscription Required

ACOs Meet With Hill Staff On MACRA Reform

(3/9, Jalen Brown, Inside Health Policy) reports “...According to the source, discussions with congressional offices have focused on two central goals: stabilizing physician payment updates and strengthening incentives for clinicians to move into alternative payment models (APMs) and other value-based care arrangements.” Subscription Required